Prostate Cell News Volume 12.09 | Mar 12 2021

    0
    50







    2021-03-12 | PCN 12.09


    Prostate Cell News by STEMCELL Technologies
    Vol. 12.09 – 12 March, 2021
    TOP STORY

    A Noncanonical AR Addiction Drives Enzalutamide Resistance in Prostate Cancer

    By performing genome-wide ChIP-seq profiling in enzalutamide-resistant castration-resistant prostate cancer cells, scientists identified a set of androgen receptor (AR) binding sites with increased AR binding intensity.
    [Nature Communications]

    Full Article

    Enter a contest to win a personalized lab coat by subscribing to Organoid News!
    PUBLICATIONSRanked by the impact factor of the journal

    An Arf GTPase Module Promoting Invasion and Metastasis through Regulating Phosphoinositide Metabolism

    The authors report the development of 3D culture analyses to separately quantify growth and invasion. They identified that alternate variants of IQSEC1, an ARF GTPase Exchange Factor, acted as switches to promote invasion over growth by controlling phosphoinositide metabolism.
    [Nature Communications]

    Full Article

    Nuclear βArrestin1 Regulates Androgen Receptor Function in Castration Resistant Prostate Cancer

    Scientists identified ubiquitous βArrestin 1 as a regulator of androgen receptor function in castration-resistant prostate cancer.
    [Oncogene]

    Abstract

    Development of EphA2 siRNA-Loaded Lipid Nanoparticles and Combination with a Small-Molecule Histone Demethylase Inhibitor in Prostate Cancer Cells and Tumor Spheroids

    Investigators developed cationic solid lipid nanoparticles to carry siRNAs targeting EphA2 receptor tyrosine kinase (siEphA2), which is overexpressed in many solid tumors including prostate cancer.
    [Journal of Nanobiotechnology]

    Full ArticleGraphical Abstract

    2D Exfoliated Black Phosphorus Influences Healthy and Cancer Prostate Cell Behaviors

    Researchers investigated nanostructured exfoliated black phosphorus in vitro effect on healthy and cancer prostate cell behavior.
    [Scientific Reports]

    Full Article

    GLIPR1 and SPARC Expression Profile Reveals a Signature Associated with Prostate Cancer Brain Metastasis

    Scientists analyzed the molecular profile, as well as the functional consequences involved in the reciprocal interactions between prostate tumor cells and human astrocytes.
    [Molecular and Cellular Endocrinology]

    Abstract

    Inhibition of Human Prostate Stromal Cell Growth and Smooth Muscle Contraction by Thalidomide: A Novel Remedy in LUTS?

    Researchers investigated the effect of thalidomide on cellular functions of prostate stromal cells and human prostate smooth muscle contraction.
    [Prostate]

    Full Article

    Investigation of Molecular Mechanisms Underlying the Antiproliferative Effects of Colchicine against PC3 Prostate Cancer Cells

    Investigators examined the cytotoxic effects of colchicine on PC3 cells to elucidate their possible underlying mechanisms.
    [Toxicology in Vitro]

    AbstractGraphical Abstract

    Overcoming TRAIL-Resistance by Sensitizing Prostate Cancer 3D Spheroids with Taxanes

    DU145 and PC3 cells were cultured as 2D monolayers and 3D spheroids to compare sensitization of TRAIL-resistance cancer cells to TRAIL-mediated apoptosis via chemotherapy based on dimensionality.
    [PLoS One]

    Full Article

    Scientific resources to support your organoids research. Learn More!
    REVIEWS

    Orphan Nuclear Receptors as Regulators of Intratumoral Androgen Biosynthesis in Castration-Resistant Prostate Cancer

    The authors present an overview of the current understanding of the intratumoral androgen biosynthesis in castration-resistant prostate cancer, with a special focus on the emerging roles of orphan nuclear receptors in this process.
    [Oncogene]

    Full Article

    INDUSTRY AND POLICY NEWS

    GT Biopharma Announces Preclinical Results for Its ROR1 TriKEâ„¢ as a Treatment for Prostate Cancer

    GT Biopharma, Inc. announced preclinical results for its ROR1 TriKEâ„¢ product candidate as a prospective therapy for the treatment of prostate cancer.
    [GT Biopharma, Inc.]

    Press Release

    Orca Therapeutics to Start Highest Dose in Treatment-Naïve Prostate Cancer

    ORCA Therapeutics B.V. announced that upon review of all safety data from the fully enrolled, low- and mid-dose patient cohorts of the ongoing Phase I/IIa clinical study of ORCA-010 in treatment-naïve patients with localized prostate cancer, the independent Data and Safety Monitoring Board recommended the continuation of the study without modification.
    [ORCA Therapeutics B.V]

    Press Release

    FEATURED EVENT

    EMBO Workshop: Cancer Immunometabolism

    November 29 – December 1, 2021
    Barcelona, Spain

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scholar Position – Hormone Therapy Resistance in Prostate Cancer

    Duke University – Durham, North Carolina, United States

    Postdoctoral Position – Prostate Cancer Biology

    Weill Cornell Medicine – New York, New York, United States

    Postdoctoral Fellow – Prostate Cancer Foundation

    Lerner Research Institute – Cleveland, Ohio, United States

    Postdoctoral Fellow – Prostate Cancer

    H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States

    Chair – Urology

    Weill Cornell Medicine – New York, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter